What is CUBT stock price today?

CUBT (Curative Biotechnology Inc) stock is trading at $0.01 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is CUBT stock going up or down today?

CUBT stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy CUBT stock now?

The decision to buy CUBT depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is CUBT a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for CUBT based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is CUBT stock overvalued or undervalued?

Use our DCF valuation calculator to determine if CUBT is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is CUBT's P/E ratio?

P/E ratio data for CUBT will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is CUBT's market cap?

CUBT (Curative Biotechnology Inc) has a market capitalization of $0.01 billion, making it a small-cap stock.

What is CUBT's price to book ratio?

Price-to-book ratio for CUBT is available on our dashboard along with other valuation metrics.

Does CUBT pay dividends?

CUBT does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is CUBT's dividend yield?

CUBT does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is CUBT stock a good long-term investment?

CUBT's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is CUBT's revenue growth rate?

Revenue growth data for CUBT is available on our dashboard with detailed financial statement analysis.

Profitability metrics for CUBT are available on our dashboard with complete income statement analysis.

What are the risks of investing in CUBT?

Key risks for CUBT include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does CUBT compare to its competitors?

Compare CUBT to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize CUBT's performance and positioning.

What is CUBT's stock price target for 2026?

Our AI model provides price targets for CUBT based on fundamental analysis: Bull case $0.01 (+30%), Base case $0.01 (+15%), Bear case $0.01 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about CUBT?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for CUBT. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is CUBT's next earnings report?

CUBT reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

CUBT - Curative Biotechnology Inc

NYSE * Healthcare * Biotechnology

$0.01

$-0.00 (-9.76%)

About Curative Biotechnology Inc

Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Palm Beach Gardens, Florida.

CUBT Key Statistics

Market Cap

$6.54M

000

How CUBT Compares to Peers

CUBT is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
CUBT(This stock)	$6.54M	N/A	0%	0.0%	-
AMGNAmgen Inc	$178.24B	25.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$154.03B	19.2	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.35B	31.2	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$77.77B	17.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$24.26B	15.1	0%	0.2%	vs BIIB

Curative Biotechnology Inc Company Information

Headquarters: 3801 PGA Blvd, Palm Beach Gardens, FL, United States, 33410, undefined
Website: curativebiotech.com
Sector: Healthcare
Industry: Biotechnology

Data Updated: January 21, 2026 at 5:57 AM EST

Ready to invest in CUBT?

Commission-free trading available. Affiliate links.

Upcoming Events for CUBT

Dashboard

Enter a ticker to analyze